Back to Search
Start Over
The effectiveness of natalizumab vs fingolimod – a comparison of international registry studies
- Source :
- Multiple Sclerosis and Related Disorders; 20210101, Issue: Preprints
- Publication Year :
- 2021
-
Abstract
- Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening.
Details
- Language :
- English
- ISSN :
- 22110348
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Multiple Sclerosis and Related Disorders
- Publication Type :
- Periodical
- Accession number :
- ejs56163785
- Full Text :
- https://doi.org/10.1016/j.msard.2021.103012